Fundz

Aptose Biosciences

San Diego, California, United States · Biotechnology, Health Care, Medical

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.

Key facts

Headquarters
San Diego, California, United States
Employees
35
Industries
Biotechnology, Health Care, Medical
Website
aptose.com
LinkedIn
Company page

Recent activity at Aptose Biosciences

  • : SEC 8-K (7.01): On June 30, 2026, Aptose Biosciences Inc. issued a Regulation FD disclosure through a press release. This press release contains information that is not to be considered formally 'filed' under the Securities Exchange Act, indicating that the content may pertain to significant corporate updates important for investors. While the exact details of the disclosure are cited to be in the attached Exhibit 99.1, the timing of this communication following 2026-06-28 suggests it is timely and relevant for shareholders.
  • : SEC 8-K (5.02): On June 30, 2026, all directors of the Company resigned as part of a corporate restructuring related to the consummation of the Arrangement. Notably, these resignations were not due to any disagreements but rather were a planned transition marked by the completion of the Arrangement. The same date also saw the Company notify the Toronto Stock Exchange to delist its Common Shares, expected to occur on or about July 3, 2026. This transition is significant as it reflects a strategic shift in governance following the Arrangement's completion.
  • : SEC 8-K (7.01): On June 15, 2026, Aptose Biosciences Inc. issued a press release outlining important company developments. This disclosure was made in compliance with Regulation FD, indicating the company's commitment to fair disclosure of material information. The document highlights key details intended for investors and analysts, with implications for the company's market position. The press release, attached as Exhibit 99.1, serves to enhance transparency following significant corporate activities or announcements. No specific financial amounts were mentioned, but the timing aligns with the recent disclosure requirements.
  • : SEC 8-K (7.01): On May 29, 2026, Aptose Biosciences Inc. issued a press release regarding significant developments within the company. This Regulation FD Disclosure provides transparency and compliance with regulatory requirements as set forth in the Securities Exchange Act. The information provided is not deemed 'filed' under the Act, but is intended to inform stakeholders of ongoing corporate actions. Additional details can be found in Exhibit 99.1 attached to the filing.
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01): On March 31, 2026, Aptose Biosciences Inc. issued a press release concerning recent developments. The content of the press release is attached as Exhibit 99.1. As per the press release, the disclosures made are not considered 'filed' under the Securities Exchange Act of 1934, which indicates that the information may pertain to operational updates or material events impacting the company. The exact details of the disclosures will need to be reviewed in the attachment provided to understand the implications for stakeholders. This action highlights the company's commitment to transparency and compliance with regulatory standards.
  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01): On March 23, 2026, Aptose Biosciences Inc. issued a Regulation FD disclosure through a press release. This disclosure provides important information that may be of interest to security holders, although specific details about the content of the press release are not mentioned in the filing. The press release is attached as Exhibit 99.1 and is intended for regulatory compliance under the Securities Exchange Act. The event date aligns with the filing date, reflecting timely communication to investors.
  • : SEC 8-K (7.01): On March 19, 2026, Aptose Biosciences Inc. issued a press release regarding significant corporate developments. The press release is attached as Exhibit 99.1 and not deemed 'filed' for regulatory purposes. While specific details of the disclosure are not mentioned in this filing summary, the timing suggests important updates relevant to shareholders. The filing indicates a proactive approach to communication in compliance with Regulation FD, emphasizing the company's commitment to transparency in its operations and overall corporate governance.
  • : SEC 8-K (1.01): On February 23, 2026, Aptose Biosciences Inc. entered into an Amended and Restated Arrangement Agreement with Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd., involving the acquisition of all common shares of Aptose that are not currently owned by the Hanmi Purchasers. This amendment updates the meeting date from January 16, 2026, to March 31, 2026. Furthermore, on the same date, the company entered a second amended and restated facility agreement with Hanmi for US$11.1 million to fund business and clinical operations related to Tuspetinib, with advances capped at US$4.2 million per transaction and accruing interest at 6% per annum. These agreements indicate a significant strategic partnership and funding arrangement aimed at advancing Aptose's operations and growth.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Aptose Biosciences funding history

DateRoundAmount
Jun 2024Seed$4.4M
Sep 2023Seed$3.0M

Leadership

  • William G. Rice, President
  • Alex Chang, Director
  • Fletcher Payne, Chief Financial Officer

Verified email and direct lines for Aptose Biosciences’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Aptose Biosciences files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Aptose Biosciences in the news

Companies similar to Aptose Biosciences

  • Faeth Therapeutics · Biotechnology, Health Care, Medical, research, Therapeutics
  • Swarm Oncology Ltd · Biotechnology, Health Care, Medical, research, Therapeutics
  • Onward Therapeutics SA · Biotechnology, Health Care, Medical, research, Therapeutics
  • Celldex · Biotechnology, Health Care, Medical, research, Therapeutics
  • Genentech · Biotechnology, Health Care, Medical, research, Therapeutics

About Aptose Biosciences: questions and answers

What does Aptose Biosciences do?

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.

Where is Aptose Biosciences headquartered?

Aptose Biosciences is headquartered in San Diego, California, United States.

How many employees does Aptose Biosciences have?

Aptose Biosciences has about 35 employees.

Has Aptose Biosciences raised funding?

Yes. Fundz has recorded 2 funding events for Aptose Biosciences. The most recent, Seed of $4.4M, was in Jun 2024.

Who leads Aptose Biosciences?

William G. Rice is a President at Aptose Biosciences.

What is the latest news on Aptose Biosciences?

On Oct 16, 2025, SEC 8-K (7.01): On June 30, 2026, Aptose Biosciences Inc. issued a Regulation FD disclosure through a press release. This press release contains information that is not to be considered formally 'filed' under the Securities Exchange Act, indicating that the content may pertain to significant corpora

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Aptose Biosciences across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.